A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis
Status:
Recruiting
Trial end date:
2022-04-06
Target enrollment:
Participant gender:
Summary
A randomised, adaptive design, double-blind, placebo-controlled, first-in-human, two-part
study to investigate the safety, tolerability, PK and preliminary efficacy of multiple
topical doses of BEN2293 in patients with mild to moderate AD.